A Recombinant Vaccine for COVID-19
The Korean Ministry of Food and Drug Safety has approved a clinical trial of COVID-19 vaccine "EuCOVAC-19" developed by EuBiologics.
The ministry said on Jan. 21 that it has thus far given clinical trial approval to seven COVID-19 vaccines, including EuCOVAC-19, and 15 COVID-19 treatments.
The clinical trial is aimed at evaluating EuCOVAC-19’s safety and immunogenicity for healthy adults, and will proceed with Phase 1 and Phase 2 sequentially.
EuCOVAC-19 is a recombinant vaccine based on surface antigen proteins from the COVID-19 virus. The vaccine's surface antigen proteins form neutralizing antibodies by stimulating immune cells. When the COVID-19 virus breaks into the body, the antibodies kill the COVID-19 virus.
Currently, Novavax of the United States and other pharmaceutical companies are conducting clinical trials of COVID-19 vaccines using genetic recombination technology.
Currently, the seven vaccines approved for clinical trials in Korea include three DNA vaccines, INO-4800 of the International Vaccine Institute, GX-19N of Genexine and GLS-5310 of GeneOne Life Science, which are all in clinical trial phases 1 and 2; three recombinant vaccines -- SK Bioscience’s NBP2001 in phase 1 and SK Bioscience’s GBP510 and EuBiologics’ EuCOVAC-19 in phases 1 and 2; and a virus vector vaccine -- Cellid’s AdCLD-CoV19 in phases 1 and 2.